Eton Pharmaceuticals (ETON) Expected to Release Quarterly Earnings on Thursday

Eton Pharmaceuticals (NASDAQ:ETON) is expected to be releasing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of $0.13 per share and revenue of $27.1130 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:30 PM ET.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its earnings results on Thursday, May 14th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.05). The firm had revenue of $24.27 million for the quarter, compared to analyst estimates of $22.31 million. Eton Pharmaceuticals had a negative net margin of 1.70% and a negative return on equity of 5.68%. On average, analysts expect Eton Pharmaceuticals to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Eton Pharmaceuticals Stock Performance

Shares of Eton Pharmaceuticals stock opened at $45.14 on Tuesday. The stock has a market cap of $1.24 billion, a PE ratio of -644.77 and a beta of 0.86. The business has a fifty day simple moving average of $36.23 and a 200-day simple moving average of $26.77. The company has a quick ratio of 0.88, a current ratio of 1.21 and a debt-to-equity ratio of 0.62. Eton Pharmaceuticals has a 12 month low of $13.98 and a 12 month high of $50.18.

Insider Activity

In related news, insider David Krempa sold 19,679 shares of the business’s stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $31.47, for a total value of $619,298.13. Following the completion of the sale, the insider owned 25,249 shares of the company’s stock, valued at approximately $794,586.03. The trade was a 43.80% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Jennifer Mckie Adams sold 50,000 shares of the stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $32.48, for a total value of $1,624,000.00. Following the completion of the transaction, the director owned 50,000 shares in the company, valued at $1,624,000. This represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 150,000 shares of company stock valued at $4,853,921. 16.49% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Intech Investment Management LLC lifted its holdings in Eton Pharmaceuticals by 11.1% in the 4th quarter. Intech Investment Management LLC now owns 12,421 shares of the company’s stock worth $210,000 after purchasing an additional 1,244 shares during the last quarter. PharVision Advisers LLC acquired a new position in Eton Pharmaceuticals during the third quarter valued at approximately $229,000. Voleon Capital Management LP acquired a new position in Eton Pharmaceuticals during the third quarter valued at approximately $238,000. Alliancebernstein L.P. bought a new position in shares of Eton Pharmaceuticals in the third quarter valued at approximately $209,000. Finally, Engineers Gate Manager LP bought a new position in shares of Eton Pharmaceuticals in the second quarter valued at approximately $198,000. Institutional investors own 27.86% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Wall Street Zen raised Eton Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 13th. Craig Hallum upped their target price on Eton Pharmaceuticals from $40.00 to $62.00 and gave the company a “buy” rating in a report on Tuesday, July 28th. HC Wainwright raised their price target on shares of Eton Pharmaceuticals from $52.00 to $57.00 and gave the stock a “buy” rating in a report on Friday, May 15th. Canaccord Genuity Group assumed coverage on shares of Eton Pharmaceuticals in a research report on Thursday, July 16th. They set a “buy” rating and a $60.00 price objective on the stock. Finally, Zacks Research lowered shares of Eton Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $52.50.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.